Alterity Therapeutics Limited (ATHE) |
| 3.4 -0.12 (-3.41%) 01-13 16:00 |
| Open: | 3.42 |
| High: | 3.42 |
| Low: | 3.4 |
| Volume: | 6,610 |
| Market Cap: | 31(M) |
| PE Ratio: | -5.4 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.19 |
| Resistance 1: | 3.59 |
| Pivot price: | 3.22 |
| Support 1: | 3.02 |
| Support 2: | 2.66 |
| 52w High: | 7 |
| 52w Low: | 2.52 |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Financials
| EPS | -0.560 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.293 |
| Profit Margin (%) | -223.35 |
| Operating Margin (%) | -185.73 |
| Return on Assets (ttm) | -28.1 |
| Return on Equity (ttm) | -43.2 |
Company news
Thu, 20 Nov 2025
Alterity (ATHE) CEO Discusses Progress Towards Phase 3 FDA Meeti - GuruFocus
Wed, 12 Nov 2025
Alterity (NASDAQ: ATHE) schedules Nov. 19 presentation at Bell Potter virtual conference - Stock Titan
Mon, 10 Nov 2025
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System - GlobeNewswire
Thu, 09 Oct 2025
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders - GlobeNewswire
Thu, 02 Oct 2025
Alterity Therapeutics to Deliver Multiple Presentations at - GlobeNewswire
Tue, 30 Sep 2025
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
